Ministry Invites Public Comments on Draft Amendment to the Drugs Rules, 1945 to Update Testing Norms for Blood Products

Proposed Amendment to Drugs Rules Seeks to Remove Duplicate Viral Testing of Blood Products and Align with Global Pharmacopoeial Standards Posted On: 11 MAR 2026 9:37AM by PIB Delhi The Ministry of Health and Family Welfare (MoHFW), Government of India, has issued a draft Gazette Notification GSR 164(E) dated 9 th March 2026, inviting public comments on a proposal to amend Para G (Testing of Blood Products), Part XII C, Schedule F of the Drugs Rules 1945. The proposed amendment seeks to align regulatory requirements for testing of blood products with internationally accepted pharmacopoeial standards and to remove additional testing requirements on products that are not warranted under global best practices. As per the official monographs of Human Plasma for Fractionation in the Indian Pharmacopoeia (IP), British Pharmacopoeia (BP), United States Pharmacopeia (USP), and European Pharmacopoeia (EP), stringent testing protocols are prescribed for pooled human plasma. Under these harmonized standards: The first homogeneous pool of plasma is mandatorily tested for Hepatitis B surface antigen (HBsAg), Hepatitis C virus RNA and antibodies to HIV. The pooled plasma must test negative for these viral markers before it is permitted for fractionation. Only plasma pools that meet these safety requirements are used for manufacturing plasma-derived medicinal products. Despite this, under the current regulatory framework, the final products manufactured from already tested and qualified plasma pools are again tested. This results in duplication of testing for the same viral markers at both the pooled plasma stage and the finished product stage. Such double testing is not aligned with international regulatory practices. The proposed amendment is a progressive step towards regulatory harmonization, scientific rationalization of testing requirements, and reduction of avoidable compliance burden while continuing to uphold the highest standards of patient safety. Stakeholders are encouraged to review the draft notification and submit their comments and suggestions within the prescribed timeline. *** SR HFW&ndash;Public Comments Invited on Draft Amendment to Blood Product Testing Norms/11 th March 2026/1 (Release ID: 2237960) Visitor Counter : 1069 Read this release in: Urdu , Marathi , हिन्दी , Punjabi , Gujarati , Tamil , Kannada , Malayalam Ministry of Health and Family Welfare Ministry Invites Public Comments on Draft Amendment to the Drugs Rules, 1945 to Update Testing Norms for Blood Products Proposed Amendment to Drugs Rules Seeks to Remove Duplicate Viral Testing of Blood Products and Align with Global Pharmacopoeial Standards Posted On: 11 MAR 2026 9:37AM by PIB Delhi The Ministry of Health and Family Welfare (MoHFW), Government of India, has issued a draft Gazette Notification GSR 164(E) dated 9 th March 2026, inviting public comments on a proposal to amend Para G (Testing of Blood Products), Part XII C, Schedule F of the Drugs Rules 1945. The proposed amendment seeks to align regulatory requirements for testing of blood products with internationally accepted pharmacopoeial standards and to remove additional testing requirements on products that are not warranted under global best practices. As per the official monographs of Human Plasma for Fractionation in the Indian Pharmacopoeia (IP), British Pharmacopoeia (BP), United States Pharmacopeia (USP), and European Pharmacopoeia (EP), stringent testing protocols are prescribed for pooled human plasma. Under these harmonized standards: The first homogeneous pool of plasma is mandatorily tested for Hepatitis B surface antigen (HBsAg), Hepatitis C virus RNA and antibodies to HIV. The pooled plasma must test negative for these viral markers before it is permitted for fractionation. Only plasma pools that meet these safety requirements are used for manufacturing plasma-derived medicinal products. Despite this, under the current regulatory framework, the final products manufactured from already tested and qualified plasma pools are again tested. This results in duplication of testing for the same viral markers at both the pooled plasma stage and the finished product stage. Such double testing is not aligned with international regulatory practices. The proposed amendment is a progressive step towards regulatory harmonization, scientific rationalization of testing requirements, and reduction of avoidable compliance burden while continuing to uphold the highest standards of patient safety. Stakeholders are encouraged to review the draft notification and submit their comments and suggestions within the prescribed timeline. *** SR HFW&ndash;Public Comments Invited on Draft Amendment to Blood Product Testing Norms/11 th March 2026/1 (Release ID: 2237960) Proposed Amendment to Drugs Rules Seeks to Remove Duplicate Viral Testing of Blood Products and Align with Global Pharmacopoeial Standards" /> <span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">The Ministry of Health and Family Welfare (MoHFW), Government of India, has issued a draft Gazette Notification GSR 164(E) dated 9th March 2026, inviting public comments on a proposal to amend Para G (Testing of Blood Products), Part XII C, Schedule F of the Drugs Rules 1945.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">The proposed amendment seeks to align regulatory requirements for testing of blood products with internationally accepted pharmacopoeial standards and to remove additional testing requirements on products that are not warranted under global best practices.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">As per the official monographs of Human Plasma for Fractionation in the Indian Pharmacopoeia (IP), British Pharmacopoeia (BP), United States Pharmacopeia (USP), and European Pharmacopoeia (EP), stringent testing protocols are prescribed for pooled human plasma.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">Under these harmonized standards:</span></span></p> <ul> <li style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">The first homogeneous pool of plasma is mandatorily tested for Hepatitis B surface antigen (HBsAg), Hepatitis C virus RNA and antibodies to HIV.</span></span></li> <li style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">The pooled plasma must test negative for these viral markers before it is permitted for fractionation.</span></span></li> <li style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">Only plasma pools that meet these safety requirements are used for manufacturing plasma-derived medicinal products.</span></span></li> </ul> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">Despite this, under the current regulatory framework, the final products manufactured from already tested and qualified plasma pools are again tested.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">This results in duplication of testing for the same viral markers at both the pooled plasma stage and the finished product stage. Such double testing is not aligned with international regulatory practices.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">The proposed amendment is a progressive step towards regulatory harmonization, scientific rationalization of testing requirements, and reduction of avoidable compliance burden while continuing to uphold the highest standards of patient safety.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">Stakeholders are encouraged to review the draft notification and submit their comments and suggestions within the prescribed timeline.</span></span></p> <p style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">***</span></span></p> <p><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px"><strong>SR</strong></span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">HFW&ndash;Public Comments Invited on Draft Amendment to Blood Product Testing Norms/11th March 2026/1</span></span></p> " /> var mPlayer = document.getElementById("background_music"); var mPlayAction = document.getElementById("playbutton"); var isPlaying = false; function playAudio() { mPlayer.play(); isPlaying = true; document.getElementById('stopA').style.display = "block"; document.getElementById('playA').style.display = "none"; } function pauseAudio() { mPlayer.pause(); isPlaying = false; document.getElementById('playA').style.display = "block"; document.getElementById('stopA').style.display = "none"; } //function HandleAudio() { // if (isPlaying == true) { // //Playing already Pause it // pauseAudio(); // } else { // //Play the music // playAudio(); // } //} var synth = window.speechSynthesis; function CleanHtml(html) { html = html.replace(/ /gi, ''); return html; } function stripHtml(html) { let tmp = document.createElement("DIV"); tmp.innerHTML = CleanHtml(html); return tmp.textContent || tmp.innerText || ""; } $(document).ready(function () { //for responsive tables $("table").each(function () { if (!$(this).closest(".table-responsive").length) { $(this).wrap(" "); } }); var width = $(window).width(); if (width $(document).ready(function () { var width = $(window).width(); if (width @media print { .sticky-social, .sticky-social_mb, .pull-right, #printPDF { display: none !important; } } .f_vl { padding-right: 30px; font-size: 17px; cursor: pointer; } .log_oo { // width: 20%; display: flex; justify-content: space-between; } .log_oo img { width: 150px; /*width: 100%; height: auto;*/ } .sticky-social_mb { position: fixed; bottom: 0px; padding: 0px; margin: 0px; width: 100%; } .social_mb { list-style: none; display: flex; width: 100%; margin-bottom: -8px; } .social_mb a { padding: 8px 0px; font-size: 30px; transition: all 0.8s ease-in-out; width: 20% !important; text-align: center; } .section1 { position: relative; padding: 10px 0px; width: 100%; } .sticky-social { position: fixed; top: 20px; left: 0px; padding: 0px; margin: 0px; } .social { list-style: none; } .social a li { padding: 8px 12px; font-size: 25px; transition: all 0.8s ease-in-out; } .social a li:hover { margin-right: -30px; box-shadow: 2px 5px 10px grey; } .social a li:hover .fa { margin-left: 20px; } .fb_b { /* background-color: rgb(59, 89, 152);*/ background-color: rgba(65,103,178,255); } .twitter_r { /* background-color: rgb(29, 161, 242);*/ background-color: #000000; } .whatsapp_r { /* background-color: rgb(77, 194, 71);*/ background-color: rgba(13,191,67,255); } .fa-envelope_r { /* background-color: rgb(219, 68, 55);*/ background-color: #e2123d; } .fa-linkedin_r { background-color: rgb(0, 119, 181); } @media only screen and (max-device-width: 767px) { p span img { max-width: 90% !important; height: auto !important; } p img { max-width: 90% !important; height: auto !important; } h2 { font-size: 20px !important; font-weight: 600 !important; } h3 { font-size: 18px !important; font-weight: 600 !important; } } /* === Film Roll Badge Styling(IFFI2025 countdown) === */ .film-roll-badge { position: absolute; top:82%; right: 20px; width: 230px; height: 70px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 18px, #6e2b8b 18px, #6e2b8b 36px ); border-top: 8px solid #9a2375; border-bottom: 8px solid #9a2375; border-radius: 8px; overflow: hidden; box-shadow: 0 4px 12px rgba(0, 0, 0, 0.4); animation: moveFilm 8s linear infinite; z-index: 10; } /* film sprocket holes */ .film-roll-badge::before, .film-roll-badge::after { content: ""; position: absolute; width: 100%; height: 10px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 10px, #fff 10px, #fff 20px ); left: 0; z-index: 2; } .film-roll-badge::before { top: -4px; } .film-roll-badge::after { bottom: -4px; } .film-roll-inner { position: relative; height: 100%; display: flex; align-items: center; justify-content: center; animation: flicker 2s infinite ease-in-out; } .countdown-text { font-size: 1.3rem; font-weight: 700; color: #fff; text-shadow: 0 0 6px rgba(255, 255, 255, 0.4), 0 0 10px #000; white-space: nowrap; } /* === Animations === */ @keyframes moveFilm { 0% { background-position: 0 0; } 100% { background-position: 120px 0; } } @keyframes flicker { 0%, 100% { opacity: 1; } 50% { opacity: 0.9; } 25% { opacity: 0.95; } 75% { opacity: 0.85; } } /* === Responsive Adjustments === */ @media (max-width: 1500px) { .film-roll-badge { top: 68%; right: 18px; /* width: 220px; */ height: 65px; font-size: 0.85rem; } .press-section { margin-top: 35px; } } @media (max-width: 992px) { .film-roll-badge { top: 52%; right: 10px; width: 200px; height: 60px; } } @media (max-width: 768px) { .film-roll-badge { top: 56%; right: 10px; width: 124px; height: 55px; } .countdown-text { font-size: 0.9rem; } } @media (max-width: 576px) { .film-roll-badge { top: 59%; right: 5px; /* width: 160px; */ height: 50px; } .countdown-text { font-size: 0.85rem; } } const festivalStart = new Date("2025-11-20T00:00:00").getTime(); const festivalEnd = new Date("2025-11-28T23:59:59").getTime(); const countdownElement = document.getElementById("countdown"); const interval = setInterval(() => { const now = new Date().getTime(); // BEFORE FESTIVAL — show days + hours left if (now = festivalStart && now el.style.width = "350px"); clearInterval(interval); } }, 1000); //